RS99203A - Pirolopirimidini kao inhibitori protein kinaza - Google Patents

Pirolopirimidini kao inhibitori protein kinaza

Info

Publication number
RS99203A
RS99203A YU99203A YUP99203A RS99203A RS 99203 A RS99203 A RS 99203A YU 99203 A YU99203 A YU 99203A YU P99203 A YUP99203 A YU P99203A RS 99203 A RS99203 A RS 99203A
Authority
RS
Serbia
Prior art keywords
pyrrolopyrimidines
protein kinase
kinase inhibitors
compounds
prodrugs
Prior art date
Application number
YU99203A
Other languages
English (en)
Serbian (sr)
Inventor
Paul Joseph Cox
Tahir Nadeem Majid
Shelley Amendola
Stephanie Daniele Deprets
Chris Edlin
Brian Leslie Pedgrift
Frank Halley
Michael Edwards
Bernard Baudoin
Lain McFerlane McLay
Davis John Aldous
Original Assignee
Aventis Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Limited filed Critical Aventis Pharma Limited
Priority to MEP-193/08A priority Critical patent/MEP19308A/xx
Publication of RS99203A publication Critical patent/RS99203A/sr
Publication of RS51698B publication Critical patent/RS51698B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
YU99203A 2001-06-23 2002-06-21 Pyrrolopyrimidines as Protein Kinase Inhibitors RS51698B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-193/08A MEP19308A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds
US30167801P 2001-06-28 2001-06-28
PCT/GB2002/002835 WO2003000695A1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
RS99203A true RS99203A (xx) 2006-12-15
RS51698B RS51698B (en) 2011-10-31

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
YU99203A RS51698B (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as Protein Kinase Inhibitors

Country Status (22)

Country Link
EP (1) EP1404676A1 (xx)
JP (1) JP4344607B2 (xx)
CN (1) CN1294135C (xx)
AU (1) AU2002314325B8 (xx)
BR (1) BR0210652A (xx)
CA (1) CA2451932C (xx)
CZ (1) CZ20033443A3 (xx)
EA (1) EA007415B1 (xx)
EC (1) ECSP034922A (xx)
EE (1) EE05432B1 (xx)
GB (1) GB0115393D0 (xx)
HU (1) HUP0400300A3 (xx)
ME (1) MEP19308A (xx)
NZ (1) NZ529766A (xx)
OA (1) OA12632A (xx)
PL (1) PL374096A1 (xx)
RS (1) RS51698B (xx)
SK (1) SK15882003A3 (xx)
TN (1) TNSN03144A1 (xx)
TR (1) TR200302242T2 (xx)
UA (1) UA76760C2 (xx)
WO (1) WO2003000695A1 (xx)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
WO2005047289A1 (en) * 2003-11-17 2005-05-26 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
WO2005051393A1 (en) * 2003-11-25 2005-06-09 Pfizer Products Inc. Method of treatment of atherosclerosis
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
FR2876103B1 (fr) * 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
FR2878849B1 (fr) 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UA98449C2 (xx) 2005-12-13 2012-05-25 Инсайт Корпорейшин ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО$2,3-b]ПІРИДИНИ Й ПІРОЛО$2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ$ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПИРРОЛО$2,3-b]ПИРИДИНЫ И ПИРРОЛО$2,3-b]ПИРИМИДИНЫ КАК ИНГИБИТОРЫ ЯНУС-КИНАЗЫ
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
CN101965350A (zh) 2008-01-11 2011-02-02 纳科法尔马有限公司 作为抗癌剂的新的吡唑并[3,4-d]嘧啶衍生物
RS54560B1 (en) 2008-06-10 2016-06-30 Abbvie Inc. TRICYCLIC UNITS
LT2432472T (lt) 2009-05-22 2020-02-10 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYARY INHIBITORS OF BTK
CN104370909B (zh) 2009-12-01 2018-09-11 Abbvie 公司 三环化合物
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
CN103002875B (zh) 2010-05-21 2016-05-04 因塞特控股公司 Jak抑制剂的局部用制剂
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
CN103476776B (zh) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN102093364B (zh) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
KR101916443B1 (ko) 2012-07-26 2018-11-08 글락소 그룹 리미티드 Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸
WO2014039714A2 (en) * 2012-09-06 2014-03-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MY191357A (en) 2012-11-15 2022-06-19 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
UA120162C2 (uk) 2013-03-06 2019-10-25 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
AU2014244263A1 (en) 2013-03-13 2015-08-13 Abbvie Inc. CDK9 kinase inhibitors
AU2014244183A1 (en) 2013-03-13 2015-08-13 Abbvie Inc. Pyridine CDK9 kinase inhibitors
US9346813B2 (en) 2013-03-14 2016-05-24 Abbvie Inc. Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors
AR101528A1 (es) 2013-03-14 2016-12-28 Abbvie Inc Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina
TW201444836A (zh) 2013-03-14 2014-12-01 Abbvie Inc 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
CN104804001B9 (zh) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
AU2016340167B2 (en) 2015-10-16 2021-06-24 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
BR112019018576A2 (pt) 2017-03-09 2020-04-14 Abbvie Inc métodos de tratamento de doença de crohn e colite ulcerativa
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR20200129099A (ko) 2018-01-30 2020-11-17 인사이트 코포레이션 (1-(3-플루오로-2-(트리플루오로메틸)이소니코티닐)피페리딘-4-온)의 제조 방법
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
KR20210125471A (ko) 2018-10-05 2021-10-18 안나푸르나 바이오, 인코포레이티드 Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027199A1 (en) * 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
WO1998023613A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Fused bicyclic pyrimidine derivatives
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP4666762B2 (ja) * 1998-06-19 2011-04-06 ファイザー・プロダクツ・インク ピロロ［２．３−ｄ］ピリミジン化合物
PL347138A1 (en) * 1998-09-18 2002-03-25 Basf Ag 4-aminopyrrolopyrimidines as kinase inhibitors
KR100477818B1 (ko) * 1999-12-10 2005-03-22 화이자 프로덕츠 인코포레이티드 피롤로[2,3-ｄ] 피리미딘 화합물

Also Published As

Publication number Publication date
MEP19308A (en) 2010-06-10
GB0115393D0 (en) 2001-08-15
JP2005508300A (ja) 2005-03-31
AU2002314325B2 (en) 2009-01-08
CZ20033443A3 (en) 2004-03-17
WO2003000695A8 (en) 2004-03-11
WO2003000695A1 (en) 2003-01-03
EP1404676A1 (en) 2004-04-07
EA200400073A1 (ru) 2004-08-26
UA76760C2 (uk) 2006-09-15
BR0210652A (pt) 2004-08-10
EE05432B1 (et) 2011-06-15
TNSN03144A1 (en) 2005-12-23
HUP0400300A2 (en) 2007-08-28
HUP0400300A3 (en) 2010-12-28
CN1518552A (zh) 2004-08-04
RS51698B (en) 2011-10-31
EE200400003A (et) 2004-02-16
PL374096A1 (en) 2005-09-19
ECSP034922A (es) 2004-04-28
JP4344607B2 (ja) 2009-10-14
CN1294135C (zh) 2007-01-10
AU2002314325B8 (en) 2009-01-29
SK15882003A3 (sk) 2004-07-07
TR200302242T2 (tr) 2004-12-21
CA2451932A1 (en) 2003-01-03
OA12632A (en) 2006-06-14
CA2451932C (en) 2009-12-29
NZ529766A (en) 2008-11-28
EA007415B1 (ru) 2006-10-27

Similar Documents

Publication Publication Date Title
RS99203A (xx) Pirolopirimidini kao inhibitori protein kinaza
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
YU84603A (sh) Novi inhibitori tirozin kinaze
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
GB0112348D0 (en) Compounds
MY132106A (en) New pyridazin-3(2h)-one derivatives
EP1248612A4 (en) NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
AP1739A (en) Azaindoles
MXPA02005844A (es) Inhibidores de cinasas de proteina.
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
JO2339B1 (en) Benzamidazole compounds
MXPA05001581A (es) Algunas imidazopiridinas novedosas y su uso.
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
SE0202429D0 (sv) Novel Compounds
DE50211929D1 (en) Pyrimidinderivate
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
MXPA04005809A (es) Inhibidores de proteinas quinasas.
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
MXPA03004023A (es) Compuestos quimicos.